Acucela has announced that the first patient has enrolled in a study to evaluate emixustat hydrochloride (“emixustat”) in subjects with Stargardt disease. Approximately 30 subjects will be enrolled at 4 to 6 clinical sites in the United States, with subjects taking oral doses of the drug once daily in the evening for one month. Emixustat [Read More]
Category: Latest News
“How soon will my good eye go bad?”
This is commonly-asked by people affected with unilateral age-related macular degeneration (AMD). AMD is a chronic and progressive disease, and the chances are good that it will eventually affect both eyes. The question about when that will happen has been addressed by a three-continent study published in January 2017 by the British Journal of Ophthalmology. Researchers [Read More]
Researchers To Study Telescope Implant For Post-Cataract Patients
VisionCare, Inc. has announced FDA approval to study the company’s Implantable Miniature Telescope (IMT) in patients who have been previously treated for cataract. In the study, the new intraocular lens will be removed and replaced with the IMT in order to evaluate the safety and effectiveness of the device. For the past 8 years, the telescope implant has been improving visual acuity and quality of life [Read More]
Lucentis® Approved for Myopic Macular Degeneration
Genentech has announced FDA approval for Lucentis® as a treatment for patients with choroidal neovascularization (CNV) resulting from myopic macular degeneration (MMD), also known as myopic degeneration. Severe myopia (near-sightedness) can cause uncorrectable central vision impairment, and it may advance to total central vision loss from CNV, which is growth and leakage of blood vessels [Read More]
Photobiomodulation—A New Treatment For Dry AMD?
(Updated 11/8/17) A new non-invasive technology from LumiThera Inc. may help improve vision in people with dry age-related macular degeneration. Photobiomodulation involves exposure of the retina to light from diodes emitting red, yellow, and infrared wavelengths. Researchers in Switzerland and Toronto recently found that treating eyes three times a week for three weeks improved best [Read More]